title: Response to medical treatment in patients with Crohn's disease: the role of NOD2/CRAD15, disease phenotype, and age of diagnosis.
abstract: OBJECTIVE
  Factors influencing response to medications in Crohn's disease (CD) patients are not fully understood. We aimed to evaluate the relationships between NOD2/CARD15 mutations, disease phenotype and age of CD diagnosis and response to medical treatment with systemic steroids, azathioprine (AZA) or 6-mercaptopurine (6-MP), and infliximab.
  
  
  METHODS
  A retrospective medical records analysis was made of patients previously tested for the CD-associated NOD2/CARD15 mutations. Harvey- Bradshaw score was used to assess remission or response to therapy.
  
  
  RESULTS
  CD-associated NOD2/CARD15 mutations were not related to the rate of steroids dependency or clinical response to AZA/6-MP and infliximab. Steroid dependency was associated with colonic involvement. Thirty-three of 127 (26%) patients with colonic disease were steroid dependent, compared with 7/72 (9.7%) patients with isolated small bowel disease (ISBD), (p = 0.009). ISBD was mildly associated with a better remission/response to AZA/6-MP treatment. Disease behavior and age of diagnosis were not related to response to therapy.
  
  
  CONCLUSIONS
  Response to treatment with systemic steroids, AZA/6-MP and infliximab are not related to NOD2/CARD15 mutations, age of diagnosis and disease behavior. Patients with colonic disease have higher rates of steroid dependency.
authors.affiliation: Division of Pediatric Gastroenterology and Nutrition, Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel. weissb@sheba.health.gov.il
authors.forename: B
authors.initials: B
authors.lastname: Weiss
authors.forename: O
authors.initials: O
authors.lastname: Lebowitz
authors.forename: H H
authors.initials: HH
authors.lastname: Fidder
authors.forename: I
authors.initials: I
authors.lastname: Maza
authors.forename: A
authors.initials: A
authors.lastname: Levine
authors.forename: R
authors.initials: R
authors.lastname: Shaoul
authors.forename: S
authors.initials: S
authors.lastname: Reif
authors.forename: Y
authors.initials: Y
authors.lastname: Bujanover
authors.forename: A
authors.initials: A
authors.lastname: Karban
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D016009:Chi-Square Distribution; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D020022:Genetic Predisposition to Disease; D006801:Humans; D000069285:Infliximab; D007557:Israel; D008137:Longitudinal Studies; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008875:Middle Aged; D009154:Mutation; D053473:Nod2 Signaling Adaptor Protein / Q000235:genetics*; D010641:Phenotype; D012189:Retrospective Studies; D013256:Steroids / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; C429018:NOD2 protein, human; D053473:Nod2 Signaling Adaptor Protein; D013256:Steroids; D000069285:Infliximab; D015122:Mercaptopurine; D001379:Azathioprine
references.citation: Digestion. 2006;73(4):237-48
references.pmid: 16940727
references.citation: World J Gastroenterol. 2005 Feb 28;11(8):1187-92
references.pmid: 15754402
references.citation: Lancet. 1980 Mar 8;1(8167):514
references.pmid: 6102236
references.citation: Gastroenterology. 2001 Aug;121(2):255-60
references.pmid: 11487534
references.citation: Inflamm Bowel Dis. 2008 May;14(5):669-73
references.pmid: 18240279
references.citation: Inflamm Bowel Dis. 2008 Jun;14(6):839-49
references.pmid: 18266237
references.citation: Gut. 2006 Mar;55 Suppl 1:i16-35
references.pmid: 16481629
references.citation: J Clin Invest. 2003 Apr;111(8):1133-45
references.pmid: 12697733
references.citation: Can J Gastroenterol. 2005 Sep;19 Suppl A:5A-36A
references.pmid: 16151544
references.citation: Lancet. 2002 May 4;359(9317):1541-9
references.pmid: 12047962
references.citation: Clin Pharmacokinet. 2007;46(3):187-208
references.pmid: 17328579
references.citation: Gut. 1994 Mar;35(3):360-2
references.pmid: 8150347
references.citation: Am J Gastroenterol. 2004 Jun;99(6):1134-40
references.pmid: 15180737
references.citation: Clin Gastroenterol Hepatol. 2006 Sep;4(9):1124-9
references.pmid: 16861053
references.citation: Inflamm Bowel Dis. 2003 Jan;9(1):34-58
references.pmid: 12656136
references.citation: Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6
references.pmid: 17324398
references.citation: Am J Med Genet A. 2003 Sep 1;121A(3):240-4
references.pmid: 12923865
references.citation: Eur J Gastroenterol Hepatol. 1998 Oct;10(10):821-5
references.pmid: 9831401
references.citation: Clin Exp Immunol. 2005 Aug;141(2):357-62
references.pmid: 15996200
references.citation: J Pediatr Gastroenterol Nutr. 2007 Apr;44(4):414-22
references.pmid: 17414136
references.citation: Gastroenterology. 1996 Sep;111(3):580-6
references.pmid: 8780560
references.citation: Gastroenterology. 2002 Apr;122(4):904-15
references.pmid: 11910342
references.citation: Inflamm Bowel Dis. 2007 Jul;13(7):890-5
references.pmid: 17286275
references.citation: Gastroenterology. 2002 Jul;123(1):106-11
references.pmid: 12105838
references.citation: J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):171-9
references.pmid: 17255827
references.citation: Aliment Pharmacol Ther. 2008 May;27(9):765-70
references.pmid: 18248655
references.citation: J Pediatr. 2004 Aug;145(2):208-12
references.pmid: 15289769
references.citation: Aliment Pharmacol Ther. 2007 Oct 1;26(7):987-1003
references.pmid: 17877506